HHS Lets Compounding Pharmacies Make Six Unapproved Peptides While Rule Change Proceeds
Photo: NBC NewsThe Department of Health and Human Services said in a notice filed Wednesday that it will exercise "enforcement discretion" and not take legal action against compounding pharmacies that make six unapproved peptides while the agency works on a formal rule change. The peptides are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. In practice, pharmacies can begin offering them now, even though the substances are not yet on the Food and Drug Administration's list of ingredients that compounders may use.
None of the six is FDA-approved, and the agency's own scientists concluded there is insufficient data to show they are safe and effective. The FDA said pharmacies must certify the identity and purity of the compounds and must now report side effects, which was not previously required. Health Secretary Robert F. Kennedy Jr. and others have argued that allowing compounding would move consumers away from a gray market, where peptides are sold online as "for research use only." Online promoters have touted them for faster healing, younger-looking skin and longer life.
Left-leaning coverage leads with the process and the risks. NBC News says Kennedy took a shortcut, and The New York Times calls it a unilateral declaration by the health secretary, noting that the FDA had advised against it and that online influencers promote the products. NBC adds the specific peptide names, the new reporting duty and Kennedy's gray-market rationale. The Times excerpt stresses broad availability and the FDA's opposition. The Hill, an alternative outlet, frames the move as advancing access to peptides championed by the "Make America Healthy Again" agenda, with less emphasis on scientific doubts in the excerpt available. Right-leaning outlets had not reported this story at the time of writing, while left-leaning and alternative outlets had, and those outlets focus on the enforcement decision and its policy context.
How the sides differ Left sources stress the FDA's safety doubts and the secretary's unilateral move; alternative sources frame it as expanding access under the MAHA agenda; right sources have not covered it.
Headline, comparison and summary written by AI from the articles below. AI can make mistakes, so check the original articles before relying on a detail.
NBC News and The New York Times focus on Kennedy's unilateral shortcut, the FDA's lack of safety data and advice against it, and the gray-market argument for allowing compounding.
The Hill reports HHS will let pharmacies make and sell the peptides, presenting it as advancing access under the MAHA agenda and citing the HHS notice on enforcement discretion.